Catalog No.
Product Name
Application
Product Information
Citations
-
B7.1-CD28 Interaction Inhibitor
B7/CD28 Interaction Inhibitor 1 is a selective inhibitor of the B7.1-CD28 interaction, exhibiting an IC50 of 50 nM. This compound disrupts T-cell costimulation, making it a valuable tool for research in immunology and cancer therapy. Its ability to modulate T-cell responses highlights its potential applications in studying immune regulation and developing immunotherapeutic strategies. -
CD28 Inhibitor
DDS5 is a selective CD28 inhibitor with an affinity (kd) of 175.57 µM, effectively disrupting the CD28-CD80 interaction with an IC50 value of 332 µM. This compound is instrumental in researching immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis, enabling investigations into immune response modulation and therapeutic strategies. -
EpCAM/CD3 Bispecific Antibody
M701 is a bispecific humanized antibody that targets epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). By binding to EpCAM on tumor cells and CD3 on T cells, M701 effectively links these two cell populations, facilitating targeted cytotoxicity and enhancing T cell-mediated immune responses. This reagent is particularly valuable for research focused on advanced epithelial solid tumors, aiding in the development of innovative therapies. -
Anti-CD3E Antibody
Ebribafusp alfa is an anti-CD3E IgG4κ chimeric antibody designed to modulate immune responses by targeting the CD3 epsilon subunit of the T cell receptor complex. This compound exhibits potential therapeutic activity in autoimmune diseases and T cell-related conditions by enhancing T cell-mediated immunity. Research applications include investigations into T cell activation and modulation strategies in immunotherapy and transplant biology. -
Anti-CD3E/CD4 Antibody
Amtabafusp alfa is a humanized IgG1 λ1 antibody that targets CD3E and CD4. This recombinant antibody is designed for applications in immunology and cancer research, facilitating the study of T cell activation and tumor microenvironment interactions. It serves as a crucial tool for investigating immune responses and therapeutic strategies in various diseases. -
Anti-FOLH1/PSMA And CD3E Antibody
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody that targets FOLH1/PSMA and CD3E. This reagent effectively binds to the prostate-specific membrane antigen (PSMA) on tumor cells and to CD3E on T cells, leading to significant T cell activation. Olsutamig is primarily employed in research focused on immuno-oncology, particularly for its potential to selectively induce apoptosis in prostate cancer cells through T cell-mediated mechanisms. -
CD38 Inhibitor
CVN14 is a selective and potent inhibitor of CD38, exhibiting inhibitory activity with human and mouse IC50 values of 19 nM and 2.4 nM, respectively. This compound binds uncompetitively to CD38, forming a complex with ADPR and subsequently inhibiting its enzymatic activity. CVN14 is suitable for research applications focused on neurodegenerative diseases, providing insights into the role of CD38 in these conditions. -
CD38 Inhibitor
Luteolinidin chloride is a potent inhibitor of CD38, with a Ki value of 11.4 μM, and demonstrates significant antioxidant activity. This compound has shown to protect cardiac tissue from ischemia/reperfusion injury by preserving the functionality of endothelial nitric oxide synthase (eNOS) and preventing endothelial dysfunction. Additionally, Luteolinidin chloride acts as a competitive inhibitor of tyrosinase, with an IC50 of 3.7 μM, effectively blocking melanin production. This makes it a valuable reagent for research in cardiovascular protection and skin pigmentation studies. -
Anti-CD38 mAb/IFNα2b Fusion Protein
Modakafusp alfa is a humanized anti-CD38 IgG4 monoclonal antibody fused with two attenuated interferon-alpha 2b molecules, targeting CD38-expressing cells. It exhibits direct anti-proliferative activity against multiple myeloma cells in vitro and elicits significant and sustained antitumor responses in xenograft tumor models. Additionally, the combination of Modakafusp alfa with anti-PD-1 antibodies promotes immunomodulation and enhances antitumor efficacy, demonstrating a favorable tolerance profile in murine models. This reagent is valuable for research in multiple myeloma therapy and immune checkpoint modulation. -
CD38 Inhibitor
CD38 Inhibitor 2 is a selective inhibitor of CD38 with an IC50 range of 0.01 to 0.1 μM. This compound demonstrates potent inhibition of CD38 enzymatic activity, making it a valuable tool for studies focused on NAD+ metabolism and immune regulation. Its applications extend to cancer research, immunology, and age-related studies, contributing to a better understanding of the role of CD38 in various biological processes. -
CD38 Inhibitor
Ara-F-NAD+ is an arabino analogue of NAD+ and functions as a potent, reversible, and slow-binding inhibitor of CD38 NADase. This compound effectively modulates NAD+ metabolism, making it a valuable tool for studying the role of CD38 in various biological processes. Ara-F-NAD+ has potential applications in research focused on immune regulation, cellular signaling, and metabolic disorders related to NAD+ homeostasis. -
Anti-CD38 Antibody
Sanritatug is a humanized IgG1κ antibody that specifically targets CD38, a cell surface protein involved in immune regulation and metabolism. This antibody has demonstrated significant potential in modulating immune responses and is being investigated for therapeutic applications in various hematological malignancies and autoimmune diseases. Sanritatug may aid in the exploration of CD38's role in disease pathophysiology and the development of targeted immunotherapies. -
CD38 Inhibitor
6-Alkyne-F-araNAD is an irreversible inhibitor of CD38, a critical enzyme involved in the regulation of cyclic ADP-ribose and NAD metabolism. This compound enhances the efficacy of fluorescent probes, such as SR101-F-araNMN, allowing for improved visualization of intracellular CD38 localization. It serves as a valuable tool in studies related to immune signaling and cellular response mechanisms. -
CD38 Hydrolase Inhibitor
CD38-IN-5 is a selective inhibitor of CD38 hydrolase, exhibiting an IC50 of 4.0 μM, while sparing CD38 cyclase activity. This compound is particularly effective in enhancing natural killer (NK) cell-mediated tumor cytotoxicity and promotes increased levels of NADH+ and IFNγ in activated peripheral blood mononuclear cells (PBMCs). CD38-IN-5 serves as a valuable tool for cancer research, facilitating the investigation of immune modulation and tumor interactions. -
CD38 Inhibitor
(E/Z)-CCR-11 is a selective inhibitor of CD38, exhibiting an IC50 value of 20.8 μM against CD38 cyclase. This compound effectively enhances cellular NAD+ levels and promotes the production of interferon γ. It is valuable for research applications focused on cellular metabolism and immune response modulation. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 2 is an inhibitor that targets the interaction between Hyaluronic acid (HA) and CD44. It exhibits antiproliferative effects on CD44-positive cancer cells, effectively disrupting cancer sphere integrity and decreasing cell viability in a dose-dependent manner. This compound is suitable for applications in tumor research aimed at understanding the role of CD44 in cancer progression. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 1 is a specific inhibitor of the interaction between hyaluronic acid (HA) and CD44. By disrupting this interaction, it demonstrates significant antiproliferative effects on CD44+ cancer cell lines. This compound is valuable for research aimed at understanding cancer progression and potential therapeutic strategies targeting CD44-mediated cellular processes. -
CD47 Inhibitor
Evorpacept is a high-affinity CD47 inhibitor designed to block the CD47-SIRPα immune checkpoint interaction. By binding to CD47, Evorpacept facilitates the inhibition of wild-type SIRPα binding, enhancing immune response against tumors. This reagent is particularly relevant for research applications focused on acute myeloid leukemia and other malignancies where CD47 plays a pivotal role in immune evasion. -
CD47 Fusion Protein
Maplirpacept is a CD47 fusion protein designed to inhibit the CD47 pathway. By binding to CD47, the protein promotes phagocytosis of cancer cells, enhancing the immune response against tumors. This reagent is utilized in research focused on immuno-oncology and the modulation of immune evasion mechanisms in cancer therapy. -
Anti-MS4A1/CD47 Antibody
Amulirafusp alfa is an anti-MS4A1/CD47 IgG1κ type human antibody designed to target the MS4A1/CD47 axis. This antibody exhibits key biological activity by antagonizing CD47-mediated immune evasion, thereby enhancing phagocytosis and promoting anti-tumor immunity. It is suitable for applications in cancer immunotherapy research and studies exploring immune cell interactions in various disease models. -
Anti-CD47 Antibody
TQB-2928 is a monoclonal antibody targeting CD47, a prominent regulator of immune evasion in cancer cells. This reagent plays a crucial role in research focused on cancer immunotherapy by blocking the "don't eat me" signal that CD47 transmits to macrophages. TQB-2928 is essential for studying tumor microenvironments, immune responses, and developing therapeutic strategies aimed at enhancing anti-tumor immunity. -
CD47/SIRPα blocking peptide
Pep-20 is a CD47/SIRPα blocking peptide that inhibits the interaction between CD47 and SIRPα, demonstrating KD values of 2.91 μM for human CD47 and 3.63 μM for mouse CD47. With IC50 values of 24.56 μM and 12.03 μM, respectively, for blocking these interactions, Pep-20 exhibits significant anti-tumor activity. This peptide is useful in research applications focused on immune evasion in cancer therapies and interactions within the tumor microenvironment. -
CD47/SIRPα Blocker
NCGC00138783 free base is a selective blocker of the CD47/SIRPα interaction, exhibiting an IC50 of 50 µM. By inhibiting this axis, NCGC00138783 free base promotes immune cell activation, making it a valuable tool for research in cancer immunotherapy and immune modulation studies. Its ability to disrupt CD47 signaling can facilitate investigations into tumor evasion mechanisms and potential therapeutic strategies. -
CD47 Monoclonal Antibody
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody that targets the CD47-SIRPα interaction to induce tumor phagocytosis. This antibody preferentially binds to tumor cells over normal cells and promotes tumor cell death through a direct mechanism, independent of antibody-dependent cell-mediated cytotoxicity (ADCC). AO-176 exhibits dose-dependent antitumor effects in tumor xenograft models, making it a valuable tool for cancer research, particularly in studies involving lymphoma. -
HIV Entry Inhibitor
BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. -
TNF receptor inhibitor
AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). Inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases. -
CD73 Inhibitor
LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM. -
CD38 inhibitor
CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38. -
NTPDase inhibitor
Sodium metatungstate (POM-1) is a potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor, with Ki values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1, NTPDase 3 and NTPDase 2 respectively. -
CD47 Agonist
Thrombospondin-1 (1016-1023) is a peptide derived from the C-terminal region of Thrombospondin-1 (TSP-1) and functions as a CD47 agonist. This peptide plays a crucial role in modulating immune responses and promoting cell survival by interacting with the CD47 receptor. It is widely utilized in research focusing on immunology, cancer biology, and the study of cell migration and adhesion. -
CD37-Targeted ADC
Naratuximab emtansine is a CD37-targeted antibody-drug conjugate (ADC) that combines a humanized IgG1 monoclonal antibody with the microtubule disruptor DM1. This compound exhibits high affinity and specificity for the CD37 antigen, facilitating internalization and subsequent release of DM1 intracellularly. By disrupting microtubule assembly, Naratuximab emtansine leads to cell cycle arrest and apoptosis, making it a valuable tool for research in targeted cancer therapies and hematological malignancies. -
CD47 Agonist Peptide
Cys-PKHB1 is a CD47 agonist peptide designed to mimic thrombospondin-1. This compound has demonstrated antitumor efficacy by inducing mitochondrial alterations, the generation of reactive oxygen species (ROS), and calcium-dependent cell death in breast cancer cells. Cys-PKHB1 also promotes immune activation through immunogenic cell death, making it a valuable tool for research in cancer immunotherapy and tumor biology. -
CD45/CD148 Tyrosine Phosphatase Inhibitor
RWJ-60475 is a selective inhibitor of CD45 and CD148 tyrosine phosphatases, exhibiting an IC50 of 3.3 μM. By inhibiting these phosphatases, RWJ-60475 disrupts the phagocytic activity of macrophages, effectively blocking the invasion of Legionella pneumophila and the subsequent transport of effector proteins. This compound is valuable for research applications focused on anti-infection strategies that target host cellular factors. -
Anti-CD26 Antibody
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody that acts by inducing nuclear translocation of CD26 via the caveolin pathway. This antibody exhibits significant anti-proliferative effects on tumor cells by delaying the G2/M cell cycle transition. Additionally, YS110 is capable of inhibiting the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the interaction between MERS CoV S1 and CD26. It is a valuable tool for research applications in cancer biology and viral infections, including studies related to malignant mesothelioma and MERS. -
Anti-CD20 Antibody
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 antibody targeting the CD20 antigen on B cells. This antibody exhibits significant pro-apoptotic activity in vitro and mediates both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). In various tumor xenograft models, mAb 1.5.3 demonstrates enhanced anti-tumor efficacy. Additionally, it achieves superior B-cell depletion in lymphoid tissues and bone marrow in primate pharmacodynamic studies, making it a valuable tool for research into B-cell malignancies. -
Anti-CD37 Antibody
BI-836826 is a chimerized IgG1 monoclonal antibody targeting CD37. This antibody exhibits both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic effects, making it a valuable tool for investigating chronic lymphocytic leukemia. Its unique properties facilitate research into therapeutic applications and mechanisms of action related to CD37 in lymphoid malignancies. -
PDCD1/PD-1/CD279 Antibody
Liscastobart is a humanized IgG4κ antibody that specifically targets the programmed cell death protein 1 (PDCD1/PD-1/CD279). This antibody is instrumental in studies aimed at understanding immune regulation and checkpoint inhibition, making it valuable for cancer immunotherapy research. Its application includes assessing PD-1 blockade effects in various in vitro and in vivo models. -
interleukin-2 receptor alpha (CD25) Targeting Agent, Treg Expander
Melredableukin alfa is a bivalent conjugate targeting the interleukin-2 receptor alpha (CD25) and acts as a Treg expander. This compound demonstrates enhanced selectivity for regulatory T cells in cynomolgus monkey and humanized mouse models. Melredableukin alfa is utilized in research related to autoimmune conditions, including ulcerative colitis and autoimmune hepatitis, enabling exploration of Treg cell modulation in therapeutic contexts. -
CD47-SIRPα Signalling Inhibitor
RS17 is a CD47-SIRPα signaling inhibitor that disrupts the interaction between CD47 and its ligand, SIRPα, on macrophage surfaces. By binding to CD47, RS17 prevents the transmission of signals that enable selective phagocytosis, thereby promoting the recognition and clearance of tumor cells by macrophages. This peptide is valuable for researching anti-tumor responses and mechanisms of immune evasion in cancer.
